Huntington’s Disease (HD) Therapeutics – Pipeline Assessment and Market Forecasts to 2018

Jan. 9, 2012 - PRLog -- GlobalData estimates that the global Huntington’s Disease (HD) therapeutics market was valued at $246m in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 13.4% over the next eight years to reach $676m by 2018. This high value growth is primarily attributed to high cost of therapy of Xenazine (tetrabenazine) in the US and Huntexil (pridopidine), which is expected to launch in
2014. The current HD therapeutics market is centered around off-label use of antipsychotics (risperidone, olanzapine), antidepressants (paroxetine, citalopram) and antiepileptics (valproic acid, carbamazepine), which provide symptomatic relief.

GlobalData’s pipeline analysis revealed that there are 39 molecules in the pipeline in various stages of development. Majority of pipeline molecules are First-in-Class (FIC) with the mechanisms, aimed at delaying disease progression. The late-stage pipeline has four molecules such as HD-02 (creatine monohydrate), Huntexil, coenzyme Q10 and olanzapine. Of the four late-stage molecules, Huntexil and
HD-02 have the potential to delay disease progression.

The pipeline molecules are efficient in their respective target areas as outlined in their study results. The successful launch of these products would help provide better therapeutic options for HD patients.

Current treatment options for HD are only helpful in providing symptomatic relief. The available therapies manage movement abnormalities, mood disorder, depression and psychosis. None of the current therapies available are curative. Alternative therapies such as physiotherapy, speech therapy, occupational therapy and psychotherapy are also used to improve patients’ quality of life. HD treatment options currently lack disease-modifying and disease-delaying approved therapies. HD patients are mostly prescribed antipsychotics to provide relief from chorea and other psychiatric problems. Xenazine is the only approved therapy for treating chorea in the US, and its generic version, tetrabenazine, has been available for the last 30 years in Europe.

For Sample Pages, please click or add the below link to your browser:
http://globaldata.com/reportstore/RequestSamplePages.aspx...

HD is of genetic origin and is inherited from the parent affected with a mutated Huntingtin (HTT) gene.
The offspring of the affected parent has a 50% risk of developing symptoms of the disease. This genetic link has been well understood and appropriate genetic tests have been devised to diagnose HD. Along with this, a neurological examination is also conducted to confirm diagnosis.. This has led to the diagnosis of presymptomatic patients so that symptom-treating measures can be taken early enough to extend the survival period. An increase in the number of pre- and post-symptomatic patients being diagnosed has encouraged companies to invest in Research and Development (R&D) activities and discover the therapeutic options which could provide cure for HD.

GlobalData, the industry analysis specialist, has released its new report, “Huntington’s Disease (HD) Therapeutics – Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Huntington’s disease market. The report identifies the key trends shaping and driving the global Huntington’s disease market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Huntington’s disease sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://globaldata.com/reportstore/Report.aspx?ID=Major-De...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.